Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of the formula:

X_1-X_2-X_3-Leu-X_4-Glu-Leu-X_5-X_6-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-X_7-Z_3 [SEQ.ID.NO.27]

wherein:

(a) X_1 is

(i) a group of two amino acid residues selected from the group consisting of Leu-Leu, Val-Leu, Ile-Leu, tert-Leu-Leu, Nle-Leu, and Ala-Thr, and N-acylated derivatives thereof; or

(ii) the group Z_1-Ser-Thr-Z_2-Val-Leu [SEQ.ID.NO. 28] wherein Z_1 is an amino acid residue selected from the group consisting of Leu, Val, Ile, tert-Leu, Nva, Abu, and Nle or an N-acylated derivative thereof or Z_1 is an alkanoyl group; and Z_2 is a amino acid residue selected from the group consisting of Ala, Ser, Cys, and Thr;

(b) X_2 is an amino acid residue selected from the group consisting of Gly, Glu, Asn or Aib;

(c) X_3 is an amino acid residue selected from the group consisting of Arg, Orn, Lys and ε-amidated derivatives thereof;

(d) X_4 is a group of two amino acid residues selected from the group consisting of Ser-Gln, Thr-Gln, Ala-Asn and Thr-Asn;

(e) X_5 is an amino acid residue selected from the group consisting of His, Aib, Ile, Leu and Val;

(f) X_6 is an amino acid residue selected from the group consisting of Arg, Orn and Lys and ε-amidated derivatives thereof;

(g) X_7 is a group having 6 amino acid residues selected from the group consisting of

(i) Thr-Gly-Ser-Asn-Thr-Tyr[[-NH_2]] [SEQ.ID.NO. 29];

(ii) Thr-Gly-Ser-Gly-Thr-Pro[[-NH_2]] [SEQ.ID.NO. 30];

(iii)Val-Gly-Ser-Asn-Thr-Tyr[[-NH_2]] [SEQ.ID.NO. 31];

(iv) Val-Gly-Ser-Gly-Thr-Pro[[-NH_2]] [SEQ.ID.NO. 32]; and

(h) Z_a is OH or NH_2;

with the proviso that the compound does not have the formula of any of SEQ. ID. NOS. 14 to 26; and pharmaceutically acceptable salts thereof.

2. (Original) A compound according to claim 1 wherein Z_3 is NH_2.

3. (Original) A compound according to claim 1 wherein X_2 is Gly.

4. (Original) A compound according to claim 3 wherein X_5 is His or Aib.

5. (Currently Amended) A compound according to claim 4 wherein X_4 is Ser-[[Glu]] Gln.

6. (Original) A compound according to claim 5 wherein X_7 is Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 29] or Thr-Gly-Ser-Gly-Thr-Pro-NH_2 [SEQ.ID.NO. 30].

7. (Original) A compound according to claim 6 wherein X_1 is Z_1-Ser-Thr-Z_2-Val-Leu [SEQ.ID.NO.28].

8. (Original) A compound according to claim 7 wherein X_3 and X_6 are e-amidated with a carboxylic acid having 1 to 8 carbon atoms.

9. (Currently Amended) A compound according to claim [[9]] 1 wherein Z_1 is an alkanoyl group having 1 to about 10 carbon atoms or Leu.

10. (Original) A compound according to claim 9 wherein Z_2 is Ala or Cys.

11. (Original) A compound according to claim 10 wherein Z_1 is an alkanoyl group.

12. (Original) A compound according to claim 11 wherein X_3 and X_6 are formamidated or acetamidated.

13. (Original) A compound according to claim 12 wherein Z_2 is Ala.

14. (Original) A compound according to claim 13 wherein X_3 and X_6 are Lys(For).

15. (Original) A compound according to claim 14 wherein Z_1 is 4-methylpentanoyl.

16. (Currently Amended) A compound according to claim 1 which has an amino acid sequence selected from the group consisting of:

Leu-Ser-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 1];

4-methylpentanoyl-Ser-Thr-Ala-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro [SEQ.ID.NO. 2];

Ac-Leu-Ser-Thr-Ser-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 3];

Leu-Ser-Thr-Ala-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 4];

Leu-Ser-Thr-Ser-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [[(]] [SEQ.ID.NO. 5];

Ac-Leu-Ser-Thr-Ala-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 6];

Ac-Leu-Ser-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 7];

Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Gl-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 8];

Ac-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 9];

4-methylpendanoyl-Ser-Thr-Ala-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 10];

4-methylpentanoyl-Ser-Thr-Cys-Val-Leu-Aib-Lya(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lya(For)-Leu-Gln-Thr-Tyr-Pro- Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 11];

Ala-Thr-Aib-Lys(For)-Leu-Ala-Asn-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 12]; and

Ac-Ala-Thr-Aib-Lys(For)-Leu-Ala-Asn-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 13].

17. (Original) The compound Leu-Ser-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr [SEQ.ID.NO. 1].

18. (Original) The compound 4-methylpentanoyl-Ser-Thr-Ala-Val-Leu-Aib-Lys(For)-Leu-Ser-Gln-Glu-Leu-Aib-Lys(For)-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro [SEQ.ID.NO. 2].

19. (Original) A composition comprising a compound of any of claims 1 to 18 in a pharmaceutically acceptable carrier.

20. (Withdrawn) A method of treating diabetes in a subject in need of treatment which comprises administering to said subject a therapeutically effective amount of a compound of any of claims 1, 2, 15, 16, 17 or 18.

21. (Withdrawn) A method according to claim 20 wherein said diabetes is type I diabetes.

22. (Withdrawn) A method according to claim 20 wherein said diabetes is type II diabetes.

23. (Withdrawn) A method of beneficially regulating gastrointestinal motility in a subject comprising administering to said subject a therapeutically effective amount of a compound of any of claims 1, 2, 15, 16, 17 or 18.

24. (Withdrawn) A method according to claim 23 wherein said beneficial regulation of gastrointestinal motility comprises delaying gastric emptying.

25. (Withdrawn) A method of treating a disorder selected from the group consisting of: impaired glucose tolerance; postprandial hyperglycemia; obesity; and Syndrome x; in a subject in need of treatment which comprises administering to said subject a therapeutically effective amount of a compound of any of claims 1, 2, 15, 16, 17 or 18.